China Universal Asset Management Co. Ltd. Has $2.68 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

China Universal Asset Management Co. Ltd. boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,784 shares of the biotechnology company’s stock after purchasing an additional 3,793 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in BioMarin Pharmaceutical were worth $2,681,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at $28,000. TD Private Client Wealth LLC increased its holdings in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 186 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 663 shares during the period. GAMMA Investing LLC raised its position in shares of BioMarin Pharmaceutical by 56.1% in the third quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 281 shares during the period. Finally, True Wealth Design LLC lifted its stake in shares of BioMarin Pharmaceutical by 13,400.0% during the 3rd quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company’s stock worth $57,000 after buying an additional 804 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Down 0.8 %

BMRN stock opened at $63.36 on Friday. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $12.08 billion, a P/E ratio of 37.94, a price-to-earnings-growth ratio of 0.55 and a beta of 0.29. The firm has a 50-day moving average price of $65.15 and a 200-day moving average price of $72.99.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.23). The firm had revenue of $746.00 million during the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 EPS. As a group, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on BMRN shares. Wedbush raised shares of BioMarin Pharmaceutical to a “strong-buy” rating in a report on Monday, November 4th. Evercore ISI dropped their price target on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Barclays reduced their price target on BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a research note on Friday, October 4th. Wolfe Research started coverage on BioMarin Pharmaceutical in a report on Friday, November 15th. They set an “outperform” rating and a $95.00 target price for the company. Finally, William Blair cut shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.20.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 5,278 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the sale, the executive vice president now owns 68,909 shares in the company, valued at $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.